Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification

First-line treatment for young/fit patients with chronic lymphocytic leukemia (CLL) is the combination of fludarabine, cyclophosphamide and rituximab (FCR), which has improved these patients’ progression-free survival and overall survival,[1][1] but is poorly tolerated by elderly patients or